Bronchodilator reversibility in patients with severe asthma included in the GAN registry.

K. Milger-Kneidinger (Munich, Germany), D. Skowasch (Bonn, Germany), E. Hamelmann (Bielefeld, Germany), C. Mümmler (Munich, Germany), M. Idzko (Vienna, Germany), C. Taube (Essen, Germany), A. Holtdirk (Hamm, Germany), H. Timmerman (Hamburg, Germany), R. Buhl (Mainz, Germany), S. Korn (Heidelberg und Mainz, Germany)

Source: International Congress 2022 – Allergy and asthma: biomarkers, phenotypes and real-world evidence
Session: Allergy and asthma: biomarkers, phenotypes and real-world evidence
Session type: Thematic Poster
Number: 1678

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Milger-Kneidinger (Munich, Germany), D. Skowasch (Bonn, Germany), E. Hamelmann (Bielefeld, Germany), C. Mümmler (Munich, Germany), M. Idzko (Vienna, Germany), C. Taube (Essen, Germany), A. Holtdirk (Hamm, Germany), H. Timmerman (Hamburg, Germany), R. Buhl (Mainz, Germany), S. Korn (Heidelberg und Mainz, Germany). Bronchodilator reversibility in patients with severe asthma included in the GAN registry.. 1678

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.